Anand Bhaskar's Form 4 filing
Reata Pharmaceuticals Inc (RETA) · filed Jun 16, 2023
- Accession no.
- 0001209191-23-037802
- Filed
- Jun 16, 2023
- Trade date
- Jun 14, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $239.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anand BhaskarCIK 0001890784 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2023 | Class A common stock | MOption exerciseAcquired | +1,562 | $27.32 | +$42,673.84 | 27,241 | Direct | |
| Jun 14, 2023 | Class A common stock | SSaleDisposed | −2,343 | $102.11 | −$239,243.73 | 24,898 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2023 | Class A common stock | MOption exerciseDisposed | −1,562 | $0.00 | $0 | 23,438 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.